MedPath

Orforglipron

Generic Name
Orforglipron
Clinical Trials
Related News

A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes

Phase 3
Active, not recruiting
Conditions
Type 2 Diabetes
Interventions
First Posted Date
2023-08-24
Last Posted Date
2025-04-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
399
Registration Number
NCT06010004
Locations
🇯🇵

Nakayama Clinic, Nagoya, Aichi, Japan

🇯🇵

Shinkashiwa Clinic, Kashiwa, Chiba, Japan

🇯🇵

Kashiwa City Hospital, Kashiwa, Chiba, Japan

and more 37 locations

A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Phase 3
Completed
Conditions
Type 2 Diabetes
Interventions
Drug: Placebo
First Posted Date
2023-08-02
Last Posted Date
2025-04-23
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
559
Registration Number
NCT05971940
Locations
🇺🇸

Alliance for Multispecialty Research, LLC, Norman, Oklahoma, United States

🇲🇽

Salud Cardiovascular, Guadalajara, Jalisco, Mexico

🇮🇳

BSES MG Hospital, Mumbai, Maharashtra, India

and more 85 locations

A Study of LY3502970 in Participants With Normal and Impaired Renal Function

Phase 1
Completed
Conditions
Healthy
Renal Insufficiency
Interventions
First Posted Date
2023-07-07
Last Posted Date
2024-04-23
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
24
Registration Number
NCT05936138
Locations
🇺🇸

Clinical Pharmacology of Miami, Miami, Florida, United States

🇺🇸

Advanced Pharma CR, LLC, Miami, Florida, United States

🇺🇸

Alliance For multispecialty Research, LLC, Knoxville, Tennessee, United States

and more 1 locations

A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease

Phase 3
Active, not recruiting
Conditions
Obesity
Interventions
Drug: Placebo
First Posted Date
2023-07-05
Last Posted Date
2025-04-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
236
Registration Number
NCT05931380
Locations
🇯🇵

Nihonbashi Sakura Clinic, Chuo-ku, Tokyo, Japan

🇯🇵

Heishinkai Medical Group ToCROM Clinic, Shinjuku-ku, Tokyo, Japan

🇯🇵

Fukuwa Clinic, Chuo-ku, Tokyo, Japan

and more 13 locations

A Study of LY3502970 in Participants With Impaired and Normal Liver Function

Phase 1
Completed
Conditions
Healthy
Hepatic Insufficiency
Interventions
First Posted Date
2023-05-31
Last Posted Date
2024-12-03
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
29
Registration Number
NCT05882032
Locations
🇺🇸

Clinical Pharmacology of Miami, Miami, Florida, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

🇺🇸

Texas Liver Institute, San Antonio, Texas, United States

and more 1 locations

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Phase 3
Active, not recruiting
Conditions
Overweight
Obesity
Type 2 Diabetes
Interventions
Drug: Placebo
First Posted Date
2023-05-24
Last Posted Date
2025-04-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1500
Registration Number
NCT05872620
Locations
🇦🇺

Advara HeartCare Joondalup, Joondalup, Western Australia, Australia

🇺🇸

Cahaba Research - Pelham, Pelham, Alabama, United States

🇺🇸

Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson, Arizona, United States

and more 132 locations

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Phase 3
Active, not recruiting
Conditions
Obesity
Overweight
Overweight or Obesity
Interventions
Drug: Placebo
First Posted Date
2023-05-22
Last Posted Date
2025-04-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
3000
Registration Number
NCT05869903
Locations
🇺🇸

The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States

🇺🇸

Velocity Clinical Research, Huntington Park, Huntington Park, California, United States

🇺🇸

Velocity Clinical Research, Westlake, Los Angeles, California, United States

and more 135 locations

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

Phase 1
Completed
Conditions
Healthy
Obese
Interventions
First Posted Date
2023-05-03
Last Posted Date
2024-10-02
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
52
Registration Number
NCT05841238
Locations
🇺🇸

LabCorp CRU, Inc., Madison, Wisconsin, United States

🇺🇸

Labcorp Clinical Research LP, Dallas, Texas, United States

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Phase 3
Active, not recruiting
Conditions
Type 2 Diabetes
Obesity
Overweight or Obesity
Overweight
Cardiovascular Diseases
Chronic Kidney Disease
Interventions
First Posted Date
2023-04-07
Last Posted Date
2025-04-17
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
2749
Registration Number
NCT05803421
Locations
🇺🇸

West Orange Endocrinology, Ocoee, Florida, United States

🇺🇸

Peace River Cardiovascular Center, Port Charlotte, Florida, United States

🇺🇸

Care Access - Tamarac, Tamarac, Florida, United States

and more 370 locations

A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2022-10-10
Last Posted Date
2023-02-14
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
32
Registration Number
NCT05573230
Locations
🇸🇬

Lilly Centre for Clinical Pharmacology, Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy